WeVote
Log In

Bill

Bill

LB 252

Prohibit disadvantaging insurance and Medicaid coverage for nonopioid drugs

109th Legislature (2025-2026) Introduced by Eliot Bostar

LB252 ensures Medicaid and private plans cover non-opioid pain drugs on par with opioids, blocks stricter criteria and cost-sharing, and lets clinicians seek exceptions.

Title printed. Carryover bill
0
WeVote Research Nonpartisan
Bill Summary · LB 252

Summary of Nebraska LB252 (2025)

Overview

  • Bill Number: LB252
  • Title: Prohibit disadvantaging insurance and Medicaid coverage for nonopioid drugs
  • Introduced: January 14, 2025
  • Sponsors: Primary — Senator Eliot Bostar; Committee — Banking, Commerce and Insurance (Chaired by Senator Mike Jacobson)
  • Status: Notice of hearing issued for February 24, 2025; referred to the Banking, Commerce and Insurance Committee (January 16, 2025) with a hearing notice on January 30, 2025

Purpose and Intent

  • To ensure that patients, particularly those at risk for opioid misuse, addiction, or overdose, have equal access to non-opioid drugs when covered by Medicaid or commercial insurance.
  • To prevent formulary placement or utilization management barriers from hindering prescribers’ ability to choose non-opioid pain management options.
  • The bill emphasizes equal access to non-opioid therapies and supports prescribers in making appropriate treatment decisions based on clinical judgment.

Key Provisions

Medicaid formulary protections (Section 2)

  • The Department of Health and Human Services (DHHS) must ensure that no FDA-approved non-opioid drug for pain is disadvantaged or discouraged in Medicaid coverage relative to opioid/narcotic drugs.
  • Prohibits:
    • Designating a non-opioid as nonpreferred if an opioid is preferred.
    • Establishing more restrictive utilization controls (e.g., prior authorization, step therapy) for non-opioids than for opioids.
  • Applies to FDA-approved non-opioid drugs for pain as soon as FDA approval occurs, even if not yet reviewed for formulary inclusion.
  • Applicability includes the Medicaid formulary and preferred drug list and relates to contracts with managed care organizations.

Commercial insurance protections (Section 3)

  • For commercial policies, certificates, or contracts (including self-funded plans) in Nebraska, to the extent not preempted by federal law:
    • No disadvantaging or discouragement in coverage or cost-sharing for non-opioid pain drugs compared to opioids.
    • Prohibits more restrictive coverage criteria for non-opioids than for opioids.
    • Prohibits more extensive utilization controls (e.g., prior authorization, step therapy) for non-opioids than for opioids.
    • Prohibits unfair tier placement in formularies that would increase non-opioid cost-sharing relative to opioids.
  • If a commercial policy restricts non-opioid coverage for pain, the prescribing clinician may request an exception based on professional judgment.

Exceptions and administration (Section 3)

  • Prescribing providers can seek exceptions when non-opioid treatments are clinically appropriate despite coverage restrictions.

General/intent language (Section 4)

  • Declares Nebraska’s proactive stance against opioid addiction and overdose while affirming equal access to non-opioid options.
  • Emphasizes that formulary placement and utilization management should not impede comprehensive pain management.

Repeal of existing provisions

  • The bill repeals and replaces the original 68-901 statutory section with the new framework governing Medicaid and private insurance coverage for non-opioid pain medications.

Affected Parties

  • Medicaid beneficiaries in Nebraska (via DHHS formulary decisions)
  • Commercial insurance policies, certificates, and self-funded employee benefit plans in Nebraska (subject to federal preemption)
  • Healthcare providers prescribing non-opioid and opioid pain medications
  • Managed care organizations contracting with the state

Procedural and Timeline Highlights

  • Introduced: January 14, 2025
  • Referred to: Banking, Commerce and Insurance Committee (January 16, 2025)
  • Hearing: Notice issued for February 24, 2025
  • Relevant statutory changes: Amends and repeals portions of Neb. Rev. Stat. § 68-901 (Medical Assistance Act)

Potential Impact

  • Aims to reduce disparities in pain management by improving access to non-opioid therapies.
  • Could influence formulary design, prior authorization practices, and cost-sharing structures for non-opioids versus opioids.
  • May require insurers and DHHS to review and adjust existing policies to avoid unintended barriers to non-opioid treatments.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.